Immuno-Oncology | Specialty

Dr. Vokes on Selecting Nivolumab or Pembrolizumab for Head and Neck Cancer Treatment

December 28th 2016

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses how to choose between nivolumab (Opdivo) and pembrolizumab (Keytruda) for second-line treatment for patients with head and neck cancer.

Give Precision Medicine a Chance

December 28th 2016

Negative reports evaluating molecularly selected agents should not derail the process of developing future therapies by employing a precision medicine approach.

Dr. Puzanov on Sequencing Targeted Therapy and Immunotherapy in Melanoma

December 27th 2016

Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses an ongoing study exploring the optimal sequence of immunotherapy agents and targeted therapies for patients with melanoma.

Stefani Spranger on the Role of CD8 T Cells in Melanoma

December 23rd 2016

Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago Medicine, discusses how the presence or absence of CD8 T cells can affect treatment approaches for patients with melanoma.

Dr. Bekaii-Saab on the Role of Immunotherapy in CRC

December 23rd 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the role of immunotherapy in the treatment of patients with colorectal cancer.

Dr. Seiwert on Prognosis for Patients With Head and Neck Cancer

December 23rd 2016

Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the current prognosis for patients with head and neck cancer prior to the FDA approvals of immunotherapy agents nivolumab (Opdivo) and pembrolizumab (Keytruda) as treatments.

Dr. Weber on Risk and Benefits With Immunotherapy Combos in Melanoma

December 23rd 2016

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the risks and benefits of combination immunotherapy as treatment for patients with melanoma.

Expert Emphasizes Importance of Liquid Biopsies in Lung Cancer

December 23rd 2016

Plasma- and urine-based assays designed to detect actionable mutations in patients with non–small cell lung cancer are changing the face of treatment for these patients.

Expert Discusses Challenges With Non-Driver Lung Adenocarcinoma

December 23rd 2016

Molecular testing is done for patients with non–small cell lung cancer to determine what genetic abnormalities are present. If a common-enough mutation is detected—such as EGFR or ALK—then patients are able to receive a targeted agent matched to that driver.

Dr. Ansell on Promise With Immunotherapy in Hodgkin Lymphoma

December 23rd 2016

Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses studies exploring PD-1 inhibitors in Hodgkin lymphoma, specifically the CheckMate-039 trial.

Dr. Hamid on Immunotherapy Approaches in Melanoma

December 22nd 2016

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses different immunotherapy approaches that oncologists are currently exploring in melanoma.

Emerging PD-L1 Inhibitors for HNSCC

December 22nd 2016

Ongoing Research of Immunotherapy in HNSCC

December 22nd 2016

Patient Selection for Nivolumab in HNSCC

December 22nd 2016

Nivolumab-Related Efficacy and Toxicity in HNSCC Patients

December 22nd 2016

Nivolumab: A New Standard-of-Care

December 22nd 2016

Immunotherapy for Recurrent HNSCC

December 22nd 2016

The Approval of Pembrolizumab for Recurrent HNSCC

December 22nd 2016

Immunotherapy for Virally Induced vs High-Mutation Burden HNSCC

December 22nd 2016

Mechanisms of Immunotherapy in HNSCC

December 22nd 2016